This complex regulatory landscape results in CLDN3’s overexpression in epithelial ovarian cancer (EOC), and ovarian epithelial inclusion cysts may potentially serve as a marker for malignancy but also as a potential target for immunotherapy [55]. The gene discussed is CLDN3; the disease is ovarian carcinoma.